BCL2 and cancer: For example, in patients with chronic lymphocytic leukemia and acute myeloid leukemia who have relapsed or refractory disease, BH3 mimetics such as Venetoclax (ABT-199), designed to mimic the activity of BH3-only proteins, can sensitize cancer cells to apoptosis by inhibiting anti-apoptotic BCL-2 family proteins (Souers et al., 2013; Roberts et al., 2016; DiNardo et al., 2019).